IGF-1 receptor inhibitors in clinical trials - Early lessons

Saravut (John) Weroha, Paul Haluska

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

The insulin-like growth factor pathway plays a major role in cancer cell proliferation, survival and resistance to anti-cancer therapies in many human malignancies, including breast cancer. As a key signaling component of IGF system, the IGF-1 receptor is the target of several investigational agents in clinical and pre-clinical development. This review will focus on the rationale for targeting the IGF-1 receptor and other components of the IGF-1 system. In addition, we will examine the role of IGF-1 signaling in resistance to clinically important breast cancer therapies, including cytotoxic chemotherapy, hormonal therapy and erbB targeted agents. We will also review the completed and ongoing clinical investigations with IGF-1 receptors inhibitors to date and the utility of these early data in designing future breast cancer studies with IGF-1 signaling inhibition strategies.

Original languageEnglish (US)
Pages (from-to)471-483
Number of pages13
JournalJournal of Mammary Gland Biology and Neoplasia
Volume13
Issue number4
DOIs
StatePublished - 2008

Fingerprint

IGF Type 1 Receptor
Insulin-Like Growth Factor I
Clinical Trials
Breast Neoplasms
Neoplasms
Somatomedins
Cell Survival
Therapeutics
Cell Proliferation
Drug Therapy

Keywords

  • Clinical trials - Phase I
  • Clinical trials - Phase II
  • Drug resistance
  • IGF-1R inhibition
  • IGFType I
  • Monoclonal antibody
  • Receptor
  • Receptor crosstalk
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

IGF-1 receptor inhibitors in clinical trials - Early lessons. / Weroha, Saravut (John); Haluska, Paul.

In: Journal of Mammary Gland Biology and Neoplasia, Vol. 13, No. 4, 2008, p. 471-483.

Research output: Contribution to journalArticle

@article{a4bf4efd464d489aaf795e348baceb09,
title = "IGF-1 receptor inhibitors in clinical trials - Early lessons",
abstract = "The insulin-like growth factor pathway plays a major role in cancer cell proliferation, survival and resistance to anti-cancer therapies in many human malignancies, including breast cancer. As a key signaling component of IGF system, the IGF-1 receptor is the target of several investigational agents in clinical and pre-clinical development. This review will focus on the rationale for targeting the IGF-1 receptor and other components of the IGF-1 system. In addition, we will examine the role of IGF-1 signaling in resistance to clinically important breast cancer therapies, including cytotoxic chemotherapy, hormonal therapy and erbB targeted agents. We will also review the completed and ongoing clinical investigations with IGF-1 receptors inhibitors to date and the utility of these early data in designing future breast cancer studies with IGF-1 signaling inhibition strategies.",
keywords = "Clinical trials - Phase I, Clinical trials - Phase II, Drug resistance, IGF-1R inhibition, IGFType I, Monoclonal antibody, Receptor, Receptor crosstalk, Tyrosine kinase inhibitors",
author = "Weroha, {Saravut (John)} and Paul Haluska",
year = "2008",
doi = "10.1007/s10911-008-9104-6",
language = "English (US)",
volume = "13",
pages = "471--483",
journal = "Journal of Mammary Gland Biology and Neoplasia",
issn = "1083-3021",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - IGF-1 receptor inhibitors in clinical trials - Early lessons

AU - Weroha, Saravut (John)

AU - Haluska, Paul

PY - 2008

Y1 - 2008

N2 - The insulin-like growth factor pathway plays a major role in cancer cell proliferation, survival and resistance to anti-cancer therapies in many human malignancies, including breast cancer. As a key signaling component of IGF system, the IGF-1 receptor is the target of several investigational agents in clinical and pre-clinical development. This review will focus on the rationale for targeting the IGF-1 receptor and other components of the IGF-1 system. In addition, we will examine the role of IGF-1 signaling in resistance to clinically important breast cancer therapies, including cytotoxic chemotherapy, hormonal therapy and erbB targeted agents. We will also review the completed and ongoing clinical investigations with IGF-1 receptors inhibitors to date and the utility of these early data in designing future breast cancer studies with IGF-1 signaling inhibition strategies.

AB - The insulin-like growth factor pathway plays a major role in cancer cell proliferation, survival and resistance to anti-cancer therapies in many human malignancies, including breast cancer. As a key signaling component of IGF system, the IGF-1 receptor is the target of several investigational agents in clinical and pre-clinical development. This review will focus on the rationale for targeting the IGF-1 receptor and other components of the IGF-1 system. In addition, we will examine the role of IGF-1 signaling in resistance to clinically important breast cancer therapies, including cytotoxic chemotherapy, hormonal therapy and erbB targeted agents. We will also review the completed and ongoing clinical investigations with IGF-1 receptors inhibitors to date and the utility of these early data in designing future breast cancer studies with IGF-1 signaling inhibition strategies.

KW - Clinical trials - Phase I

KW - Clinical trials - Phase II

KW - Drug resistance

KW - IGF-1R inhibition

KW - IGFType I

KW - Monoclonal antibody

KW - Receptor

KW - Receptor crosstalk

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=57149127369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149127369&partnerID=8YFLogxK

U2 - 10.1007/s10911-008-9104-6

DO - 10.1007/s10911-008-9104-6

M3 - Article

VL - 13

SP - 471

EP - 483

JO - Journal of Mammary Gland Biology and Neoplasia

JF - Journal of Mammary Gland Biology and Neoplasia

SN - 1083-3021

IS - 4

ER -